Texas Court Denies Novartis Request to Halt Medicaid Qui Tam Case on Constitutional Grounds
The Fifteenth Court of Appeals in Texas denied Novartis's petition for mandamus relief seeking to halt a qui tam action under the Texas Medicaid Fraud Prevention Act (TMFPA). While the court acknowledged the constitutional challenges raised by Novartis as "weighty," it ruled that these issues must be resolved through ordinary appellate review rather than through the extraordinary remedy of mandamus. The decision allows the underlying Medicaid fraud case against Novartis to proceed in the trial court. This ruling means pharmaceutical manufacturers and MCOs facing TMFPA qui tam actions cannot bypass trial proceedings by seeking immediate appellate review of constitutional defenses.
The decision limits defendants' ability to delay or dismiss Texas Medicaid fraud cases through interlocutory constitutional challenges, potentially increasing litigation exposure and settlement pressure for MCOs and their pharmacy partners facing qui tam actions.
Pharmacy · Managed Care
You might also like